Physician profile
Vy Tran
NPI 1801108311
$14,515.71
in general payments reported to CMS, 2019-2025
25 companies · $5,120 in 2025
The $5,120 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,031 · 2022: $2,318 · 2023: $2,594 · 2024: $3,453 · 2025: $5,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,964 · Consulting Fee: $1,898 · Education: $304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,964.27 |
| Consulting Fee | $1,898.00 |
| Education | $304.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $1,801.88 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $1,672.02 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $1,501.36 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $1,193.21 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $1,102.88 | 2021-2025 | |
| Dermavant Sciences, INC. | $986.49 | 2023-2024 | Vtama |
| Genzyme Corporation | $981.12 | 2021-2025 | |
| Abbvie INC. | $792.50 | 2022-2025 | |
| Galderma Laboratories, L.P. | $667.58 | 2022-2025 | Nemluvio |
| Leo Pharma INC. | $653.41 | 2021-2025 | Adbry, Anzupgo |
| Pfizer INC. | $628.36 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $517.07 | 2021-2025 | Dupixent |
| Incyte Corporation | $514.77 | 2021-2025 | Opzelura |
| Ucb, INC. | $465.39 | 2021-2025 | Bimzelx |
| Janssen Biotech, INC. | $240.37 | 2022-2025 | Tremfya |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $175.93 | 2022 | |
| Kyowa Kirin, INC. | $163.74 | 2021-2023 | Poteligeo |
| Sun Pharmaceutical Industries INC. | $131.37 | 2021-2024 | Winlevi |
| Organon LLC | $82.60 | 2025 | Vtama |
| Mayne Pharma Commercial LLC | $76.35 | 2021-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $57.83 | 2021-2025 | Cabtreo |
| Amgen INC. | $55.05 | 2021-2024 | Otezla |
| Genentech USA, INC. | $20.58 | 2023 | Xolair |
| Botanix Sb INC | $18.27 | 2025 | Sofdra |
| Kerecis Limited | $15.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vy Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.